---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-264875"
form_type: "8-K"
ticker: "JAZZ"
cik: "0001232524"
company_name: "Jazz Pharmaceuticals plc"
filed_at: "2022-10-19T23:59:59+00:00"
generated_at: "2026-06-23T02:35:18.272099+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Jazz licenses zanidatamab from Zymeworks for up to $1.76B; $50M upfront, $325M option payment

## Summary
- Exclusive rights in U.S., Europe, Japan for HER2-targeted bispecific antibody zanidatamab.
- Zymeworks eligible for $50M upfront, $325M option payment after HERIZON-BTC-01 data, plus up to $1.39B milestones.
- Tiered royalties of 10%-20% on net sales; deal expected to close in 2022 subject to HSR clearance.
- Zanidatamab in pivotal trials for biliary tract cancer and gastroesophageal adenocarcinoma.
- FDA Breakthrough Therapy and Fast Track designations; top-line BTC data expected by end of 2022.

## SEC filing metadata
- accession: 0001193125-22-264875
- form_type: 8-K
- ticker: JAZZ
- cik: 0001232524
- company_name: Jazz Pharmaceuticals plc
- filed_at: 2022-10-19T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1232524/000119312522264875/0001193125-22-264875-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1232524/000119312522264875/d496602d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-264875
- JSON: https://secwatch.observer/filing/0001193125-22-264875.json
- Plain text: https://secwatch.observer/filing/0001193125-22-264875.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.